menu
    • menu
    [{"orgOrder":0,"company":"Ypsomed","sponsor":"Civica Rx","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Peptide","year":"2023","type":"Partnership","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Ypsomed","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Ypsomed \/ Civica Rx","highestDevelopmentStatusID":"1","companyTruncated":"Ypsomed \/ Civica Rx"},{"orgOrder":0,"company":"Civica Rx","sponsor":"CalRx Biosimilar Insulin Initiative","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Partnership","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Civica Rx","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Civica Rx \/ CalRx Biosimilar Insulin Initiative","highestDevelopmentStatusID":"1","companyTruncated":"Civica Rx \/ CalRx Biosimilar Insulin Initiative"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chugai Pharmaceutical \/ Novo Nordisk","highestDevelopmentStatusID":"1","companyTruncated":"Chugai Pharmaceutical \/ Novo Nordisk"},{"orgOrder":0,"company":"Tabuk Pharmaceuticals","sponsor":"Biocon","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"SAUDI ARABIA","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Tabuk Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tabuk Pharmaceuticals \/ Biocon","highestDevelopmentStatusID":"1","companyTruncated":"Tabuk Pharmaceuticals \/ Biocon"},{"orgOrder":0,"company":"Adalvo","sponsor":"AmbioPharm","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Adalvo","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adalvo \/ AmbioPharm","highestDevelopmentStatusID":"1","companyTruncated":"Adalvo \/ AmbioPharm"},{"orgOrder":0,"company":"Kriya Therapeutics","sponsor":"QVT","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series A Financing","leadProduct":"KT-A112","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Kriya Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Kriya Therapeutics \/ QVT","highestDevelopmentStatusID":"1","companyTruncated":"Kriya Therapeutics \/ QVT"},{"orgOrder":0,"company":"Aspect Biosystems","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Aspect Biosystems","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aspect Biosystems \/ Novo Nordisk","highestDevelopmentStatusID":"1","companyTruncated":"Aspect Biosystems \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Massachusetts Institute of Technology","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Other Large Molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novo Nordisk \/ Massachusetts Institute of Technology","highestDevelopmentStatusID":"1","companyTruncated":"Novo Nordisk \/ Massachusetts Institute of Technology"},{"orgOrder":0,"company":"Quell Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Quell Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Quell Therapeutics \/ AstraZeneca","highestDevelopmentStatusID":"1","companyTruncated":"Quell Therapeutics \/ AstraZeneca"},{"orgOrder":0,"company":"AgeX Therapeutics","sponsor":"Sernova","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Recombinant Pluripotent Stem Cell-Derived Pancreatic Islet Beta Cell","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"AgeX Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AgeX Therapeutics \/ Sernova","highestDevelopmentStatusID":"1","companyTruncated":"AgeX Therapeutics \/ Sernova"},{"orgOrder":0,"company":"Evotec","sponsor":"Ildong Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"IDG16177","moa":"GPR40","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evotec \/ Ildong Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"Evotec \/ Ildong Pharmaceutical"},{"orgOrder":0,"company":"KayoThera","sponsor":"NIH NIDDK","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"KayoThera","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"KayoThera \/ NIH NIDDK","highestDevelopmentStatusID":"1","companyTruncated":"KayoThera \/ NIH NIDDK"},{"orgOrder":0,"company":"HEC Group","sponsor":"Lannett Company, Inc.","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Hormone","year":"2021","type":"Collaboration","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"HEC Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"HEC Group \/ Lannett Company, Inc.","highestDevelopmentStatusID":"1","companyTruncated":"HEC Group \/ Lannett Company, Inc."},{"orgOrder":0,"company":"Zucara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ZT-01","moa":"SST2 receptor","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Zucara Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zucara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Zucara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Diabeloop","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Hormone","year":"2023","type":"Collaboration","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Diabeloop","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Diabeloop \/ Novo Nordisk","highestDevelopmentStatusID":"1","companyTruncated":"Diabeloop \/ Novo Nordisk"},{"orgOrder":0,"company":"Tulex Pharmaceutical","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Acquisition","leadProduct":"Desmopressin Acetate","moa":"Vasopressin receptor","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Tulex Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tulex Pharmaceutical \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Tulex Pharmaceutical \/ Eton Pharmaceuticals"},{"orgOrder":0,"company":"Undisclosed","sponsor":"BIOSYENT PHARMA INC","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Undisclosed \/ BIOSYENT PHARMA INC","highestDevelopmentStatusID":"1","companyTruncated":"Undisclosed \/ BIOSYENT PHARMA INC"},{"orgOrder":0,"company":"MRM Health","sponsor":"International Flavors and Fragrances","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"BELGIUM","productType":"Other Large Molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"MRM Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MRM Health \/ International Flavors and Fragrances","highestDevelopmentStatusID":"1","companyTruncated":"MRM Health \/ International Flavors and Fragrances"},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Mina Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mina Therapeutics \/ AstraZeneca","highestDevelopmentStatusID":"1","companyTruncated":"Mina Therapeutics \/ AstraZeneca"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Regenxbio \/ Ultragenyx Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"Regenxbio \/ Ultragenyx Pharmaceutical"}]

    Find Novel Endocrinology Drugs in Clinical Development

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sanofi

                            France
                            BIO International Convention
                            Exhibiting
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Insulin Glargine,Lixisenatide

                            Therapeutic Area : Endocrinology

                            Study Phase : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            New Soliqua® Data Shows Improved Blood Sugar Control Without Weight Gain Versus Premixed Insulin

                            Details : Participants were randomized to switch from their prior insulin to either Soliqua once daily or premixed insulin twice daily, with starting doses determined and adjusted weekly. Any metformin or SGLT-2i treatment was maintained through the study period.

                            Product Name : Soliqua

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            June 28, 2021

                            Lead Product(s) : Insulin Glargine,Lixisenatide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Undisclosed

                            Country arrow
                            German Wound Congress
                            Not Confirmed

                            Undisclosed

                            Country arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Endocrinology

                            Study Phase : Undisclosed

                            Sponsor : BIOSYENT PHARMA INC

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            BioSyent In-Licenses Endocrinology Product for Canada

                            Details : Under the licensing agreement, BioSyent aims to market, sell & distribute a new endocrinology product in Canada. BioSyent and its European partner will seek Health Canada approval by the end of 2024.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            December 06, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Undisclosed

                            Sponsor : BIOSYENT PHARMA INC

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Tabuk Pharmaceuticals

                            Saudi Arabia arrow
                            German Wound Congress
                            Not Confirmed

                            Tabuk Pharmaceuticals

                            Saudi Arabia arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Endocrinology

                            Study Phase : Undisclosed

                            Sponsor : Biocon

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Biocon Signs Licensing Agreement with Tabuk Pharmaceuticals for GLP-1 Products

                            Details : The agreement will focus on commercialising GLP-1 products for diabetes and chronic weight management in select countries of the Middle East.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 27, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Undisclosed

                            Sponsor : Biocon

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Aspect Biosystems

                            Canada arrow
                            German Wound Congress
                            Not Confirmed

                            Aspect Biosystems

                            Canada arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Endocrinology

                            Study Phase : Undisclosed

                            Sponsor : Novo Nordisk

                            Deal Size : $2,675.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Aspect Biosystems And Novo Nordisk Enter Partnership To Develop Bioprinted Tissue Therapeutics For Diabetes An...

                            Details : Under the terms of the agreement, Novo Nordisk will receive an exclusive, worldwide licence to use Aspect’s bioprinting technology to develop bioprinted tissue therapeutics including up to four products for the treatment of diabetes and obesity.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $75.0 million

                            December 04, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Undisclosed

                            Sponsor : Novo Nordisk

                            Deal Size : $2,675.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Quell Therapeutics

                            United Kingdom arrow
                            German Wound Congress
                            Not Confirmed

                            Quell Therapeutics

                            United Kingdom arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Endocrinology

                            Study Phase : Undisclosed

                            Sponsor : AstraZeneca

                            Deal Size : $2,085.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Astra Zeneca Announces Agreement with Quell Therapeutics to Develop, Manufacture and Commercialise Engineered ...

                            Details : The collaboration aims to focus on the type 1 diabetes and inflammatory bowel disease using Quell’s proprietary toolbox of Treg cell engineering modules, including its innovative Foxp3 Phenotype Lock, to develop autologous multi-modular Treg cell thera...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $85.0 million

                            September 06, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Undisclosed

                            Sponsor : AstraZeneca

                            Deal Size : $2,085.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            KayoThera

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            KayoThera

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Endocrinology

                            Study Phase : Undisclosed

                            Sponsor : NIH NIDDK

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            KayoThera, Inc. Strengthens Financial Position with $5.2 Million in Grant and Expanded Series A Funding, Bring...

                            Details : The net funding will support the advancement of KayoThera’s pipeline of first-in-class antagonists of the retinoid pathway as novel oral therapies for Type 2 Diabetes.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 19, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Undisclosed

                            Sponsor : NIH NIDDK

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Sigilon Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Sigilon Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin Lispro

                            Therapeutic Area : Endocrinology

                            Study Phase : Undisclosed

                            Sponsor : Eli Lilly

                            Deal Size : $344.2 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Lilly to Acquire Sigilon Therapeutics

                            Details : Through the acquisition, Lilly will gain control of the partnered encapsulated cell therapies, including SIG-002 (human insulin), for the treatment of type 1 diabetes.

                            Product Name : SIG-002

                            Product Type : Peptide

                            Upfront Cash : $344.2 million

                            June 29, 2023

                            Lead Product(s) : Insulin Lispro

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Undisclosed

                            Sponsor : Eli Lilly

                            Deal Size : $344.2 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Diabeloop

                            France arrow
                            German Wound Congress
                            Not Confirmed

                            Diabeloop

                            France arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin

                            Therapeutic Area : Endocrinology

                            Study Phase : Undisclosed

                            Sponsor : Novo Nordisk

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Diabeloop Announces Collaboration With Novo Nordisk to Pursue Its Interoperability Strategy With Connected Ins...

                            Details : The collaboration will focus on the integration of Novo Nordisk's new generation of connected pens, NovoPen® 6 and NovoPen Echo® Plus with DBL-4pen™. Diabeloop is planning a study for Type 2 diabetes to evaluate the efficacy and clinical benefits of ...

                            Product Name : Undisclosed

                            Product Type : Hormone

                            Upfront Cash : Undisclosed

                            March 21, 2023

                            Lead Product(s) : Insulin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Undisclosed

                            Sponsor : Novo Nordisk

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Civica Rx

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Civica Rx

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin

                            Therapeutic Area : Endocrinology

                            Study Phase : Undisclosed

                            Sponsor : CalRx Biosimilar Insulin Initiative

                            Deal Size : $50.0 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            California Selects Civica Rx as Its Insulin Manufacturing Partner

                            Details : Under the agreement, Californians with diabetes will have access to Civica’s low-cost insulins via the CalRx Biosimilar Insulin Initiative. Civica will produce three insulins, glargine, lispro and aspart, available both in vials and prefilled pens unde...

                            Product Name : Undisclosed

                            Product Type : Hormone

                            Upfront Cash : Undisclosed

                            March 18, 2023

                            Lead Product(s) : Insulin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Undisclosed

                            Sponsor : CalRx Biosimilar Insulin Initiative

                            Deal Size : $50.0 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Tulex Pharmaceutical

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Tulex Pharmaceutical

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Desmopressin Acetate

                            Therapeutic Area : Endocrinology

                            Study Phase : Undisclosed

                            Sponsor : Eton Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Eton Pharmaceuticals Announces Acquisition of Rare Disease Product Candidate ET-600

                            Details : Through the acquisition, Eton will expand its portfolio with ET-600 which is an innovative product candidate under development for the treatment of an endocrinology condition.

                            Product Name : ET-600

                            Product Type : Hormone

                            Upfront Cash : Undisclosed

                            March 15, 2023

                            Lead Product(s) : Desmopressin Acetate

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Undisclosed

                            Sponsor : Eton Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth